The Goldman Guide

Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, With rare exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ.



Our Top 14 Predictions for 2014
Written by Rob Goldman   

It is not secret that this week’s trading is likely to be lower and choppy given the mid-week holiday and many of you are likely preparing for travel. With this backdrop, we give you Our Top 14 Predictions for 2014, along with a review of our 13 predictions from last year. As is the case each year, our predictions include sports, politics, and entertainment.

Read more...
 
Investing is Like Baseball
Written by Rob Goldman   
Of course an edition of the Guide would not be complete without our picks for the best sectors in the near term and 2 NYSE-traded stocks that are poised to make big moves higher. In fact, one of these stocks is a clear takeover target that is under significant accumulation---and the fun is just beginning. We are on a bit of a roll with many of our recent listed stock picks and RadioShack (NYSE – RSH) is an example of this reaching a 13% gain after last week’s profile.
Read more...
 
Ugly Ducklings Are Big Winners
Written by Rob Goldman   
What do you do when the stock market is up over 6% to new highs in just 2 weeks? Buy ugly duckling stocks. They are usually the next wave and can provide huge returns.
Read more...
 
An Investment Secret
Written by Rob Goldman   
This week we highlight a dirty little investment secret that most people think is a negative when it is really a positive, especially for the near term.
Also, check out these graphs and tables that show how small is the best place to be and has been for 10 years. Finally, we review our 3 picks last week (one hit a new high up 11%, the other hit a new high by jumping 60 %.) and update a NASDAQ biotech story that is on track to make injectable insulin a thing of the past as they have an oral insulin drug that is entering advanced clinical trials.
Read more...
 
Bonus for the Short Week
Written by Rob Goldman   
If you are seeking a couple of trades and an awesome M&A bonus for this short week, read on. Two of them are May 2013 30-30 picks (one just hit the 30-30 mark) and the other is a biotech sure to climb after turning down a cash offer that represented a 40% premium to its stock price. It could nearly double from its Friday close when it is all said and done.
Read more...
 
Predictions and 2 Stocks to Trade
Written by Rob Goldman   
Read on as to why the stock market has been like having sex with a woman who consistently fakes her orgasms. We have conducted tremendous due diligence and by reading further you will see why the market will go down another 5-7% before making a monstrous move higher. It is so obvious that this drop is a good thing because the other side’s move will be so strong. See why looking out 90 days, preparing for the big move, and trading these 2 NASDAQ stocks should earn big gains while the rest of the market twiddles its collective thumbs and can’t see the forest for the trees.
Read more...
 
The Market Hates Us
Written by Rob Goldman   
Read why the stock market hates us, peruse the identification of a key, negative lagging market indicator that we have uncovered, and the profile of a breakout M&A target.
Read more...
 
The Future of Small Stock Investors
Written by Rob Goldman   
In the "you heard it here first department," we are pretty sure we are coming to you with some incredibly useful information, well, first.
Read more...
 
Where to Put Your Money
Written by Rob Goldman   
This may be the important issue of The Goldman Guide we have published in the past 3+ years. Read on to find out: why medical marijuana and biotech stock will run and why most stocks in June will fall. Plus, we provide very scary stats, as well as what to buy and what to avoid.
Read more...
 
Is The Party Over?
Written by Rob Goldman   

This week, we review what could derail this market, followed by why it will continue to rise this year, and end it with what to expect and how to play it and a potentially bad event in May. (Hint: Buy only small caps and buy on dips.)

Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 18 of 27